|
With over 25 years of experience in biomedical research, corporate management and venture investing, Dr. Mills joined Sanderling as an Operating Partner in July 1998, and was promoted to Managing Director in 2000. Sanderling portfolio companies he previously served include Stereotaxis and Stentor, acquired by Royal Philips Electronics. Additionally, he is Chairman and CEO of Torax Medical, Taligen Therapeutics, Pulsar Vascular and Theregen and is a Director for CardioNet, Novostent, InfraReDx, and Triage Wireless. Prior to joining Sanderling, Dr. Mills served as the Corporate Vice President of New Business Development and Chief Scientific Officer of Target Therapeutics. Dr. Mills received his Ph.D. in bioengineering from the University of California, Berkeley & San Francisco School of Medicine. | 